Biophytis has appointed Pierre J. Dilda, PhD, as Director of
Research.
Pierre J. Dilda
French-Australian, Dr Dilda has more than 20 years of experience in pharmaceutical research, in both academic and industrial settings. Since 2002, he was Senior Research Fellow at the Lowy Cancer Research Center at the University of New South Wales (UNSW) in Sydney, Australia, where he was responsible for advancing several
cancer therapeutics into advanced clinical development.
At Biophytis Dr Dilda will be in charge of preclinical development for drug candidates emanating from the company’s discovery platform, including the drug-candidates targeting sarcopenic obesity and dry age related macular degeneration (AMD).
In addition, Dr. Dilda will oversee the continued utilization of the discovery platform as well as collaborations with academic and, potentially, future industrial partners.
Also, Dr Dilda will take responsibility for the companies growing intellectual property portfolio, which protects Sarcob, Macula, future molecules and related technologies.
“I am thrilled to welcome Pierre to our team,” said Stanislas Veillet, PhD, CEO of Biophytis. “His contributions will be essential for the continued application and future development of our platform for discovery of first-inclass therapeutics targeting diseases of aging. In this newly created position, Pierre will bring his international
industrial experience and support our Chief Scientific Officer and co-founder, Professor René Lafont, PhD, in advancing development of our therapeutic-candidates, enlarging our platform’s capacity and establishing our world-leading research.”